Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Clinical trial NCT04300244 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04300244
Sponsor: Åslaug Helland
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer Cancer, Lung Cancer of Lung Mesothelioma Mesothelioma; Lung Mesothelioma; Pleura Mesotheliomas Pleural

Start date: 2020-05-04
Primary completion: 2025-03-15
Enrollment: 118

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.